Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Rare Diseases

Syndrome

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Hematologic Neoplasms

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Preleukemia

Myelodysplastic Syndromes

Primary Myelofibrosis

Lymphoma

Neoplasms by Histologic Type

Hematologic Diseases

Bone Marrow Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Myeloproliferative Disorders

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Non Lymphoblastic Leukemia

Chronic Myeloid Leukemia

Acute Graft Versus Host Disease

Lymphosarcoma

Chronic Myeloproliferative Disorders

Three weekly intravenous administration of AT9283

AT9283

Hagop Kantarjian, MD

The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia. Researchers want to perform pharmacokinetic (PK) testing on blood to find out how quickly the study drug leaves the body and how the body breaks down the drug. The safety and effectiveness of this drug will also be studied.

Dose escalation study of AT9283 administered to patients with refractory hematological malignancies. Study objectives include identification of MTD and dose limiting toxicities, preliminary assessment of efficacy and definition of pharmacokinetic profile

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies

Astex Pharmaceuticals, Inc.

Heart and Blood Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks

Tony Reiman

The purpose of this study is to find out whether the new drug AT9283 will slow the growth of multiple myeloma. Side effects of AT9283 will also be closely monitored.

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

NCIC Clinical Trials Group

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias	NCT00522990	Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Myelodysplastic... Myelofibrosis	AT9283	18 Years -	Astex Pharmaceuticals, Inc.
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias	NCT00522990	Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Myelodysplastic... Myelofibrosis	AT9283	18 Years -	Astex Pharmaceuticals, Inc.
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma	NCT01145989	Multiple Myelom...	AT9283	18 Years -	Canadian Cancer Trials Group
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma	NCT01145989	Multiple Myelom...	AT9283	18 Years -	Canadian Cancer Trials Group

Spots Global Cancer Trial Database for at9283

Every month we try and update this database with for at9283 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for at9283

Every month we try and update this database with for at9283 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for at9283 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.